Drugs / DCA
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01386632 Comparator | May 2011 → Aug 2014 | head and neck squamous cell carcinoma | Sanford Health | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01386632 ↗ |
| Action | Inhibit | “Dichloroacetate (DCA), a pyruvate dehydrogenase kinase metabolic inhibitor” PMID 35312941 ↗ Mar 2022 |
| Route | Oral | “DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks” NCT01386632 ↗ |